Experienced in Factor 13 Deficiency

Nizar N. Samad-Abdel

Moncton, NB, CA 
Experienced in Factor 13 Deficiency
Moncton, NB, CA 
OverviewLocationsClinical Research

Overview

Nizar Samad-Abdel practices in Moncton, Canada. Mr. Samad-Abdel is rated as an Experienced expert by MediFind in the treatment of Factor 13 Deficiency. His top areas of expertise are Splenic Neoplasm, Factor 13 Deficiency, Chronic Lymphocytic Leukemia (CLL), Marginal Zone Lymphoma (MZL), and Splenectomy.

His clinical research consists of co-authoring 11 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Factor 13 Deficiency.

Gender
Male

Locations

Moncton, NB, Canada
Other Locations
Halifax, NS, Canada
Moncton, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2025
Intervention Type: Drug, Biological
Study Drugs: Rituximab, Bendamustine Hydrochloride, Bortezomib, Lenalidomide
Study Phase: Phase 2

11 Total Publications

Unusual Presentation of Multiple Myeloma as a Liver Tumor at Initial Diagnosis: A Case Report.
Unusual Presentation of Multiple Myeloma as a Liver Tumor at Initial Diagnosis: A Case Report.
Journal: The American journal of case reports
Published: August 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Samad-Abdel's expertise for a condition
ConditionClose
        View All 18 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile